A group of researchers from the Salk Institute, joined by scientists from academic and industry collaborators, has demonstrated that an acetyl-CoA carboxylase, or ACC, inhibitor can shrink tumors when delivered to lung cancer cells. The inhibitor targets fat synthesis, essentially cutting off one of the tumor’s sources of growth.
